Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, oxycodone orodispersible tablets (OxyNorm Dispersa®) cannot be endorsed for use within NHS Wales for the treatment of moderate to severe pain in patients with cancer and postoperative pain and treatment of severe pain requiring the use of a strong opioid. |
||
|
||
Medicine details |
||
| Medicine name | oxycodone (OxyNorm Dispersa®) | |
| Formulation | 5 mg orodispersible tablet, 10 mg orodispersible tablet, 20 mg orodispersible tablet | |
| Reference number | 1981 | |
| Indication | For the treatment of moderate to severe pain in patients with cancer and postoperative pain and treatment of severe pain requiring the use of a strong opioid. |
|
| Company | Napp Pharmaceuticals Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 22/05/2013 | |
| Date of issue | 22/05/2013 | |